Back to Search
Start Over
Immunohistochemical CD271 expression correlates with melanoma progress in a case-control study.
- Source :
-
Pathology [Pathology] 2018 Jun; Vol. 50 (4), pp. 402-410. Date of Electronic Publication: 2018 Apr 17. - Publication Year :
- 2018
-
Abstract
- Putative cancer stem cell (CSC) markers have arisen from melanoma mouse and in vitro models, but their expression in paraffin embedded patient samples relative to clinical outcome remains largely unexplored. Rather than cells of the tumour bulk, conceivably, CSC drive tumour progression. Accordingly, complete eradication may prevent melanoma relapse. Because elevated tumour-cell proliferation is an established indicator of aggressive disease, this study aimed to investigate the correlation between melanoma recurrence and proliferation of putative CSC that express CD271, CD166, or CD20. Additionally, the expression of these markers was studied in naevi, melanomas, and their recurrence. In melanoma patients, 30 with relapse (cases) and 30 without (controls) were matched for tumour thickness, ulceration, Clark level, subtype, site, gender, and age. One paraffin-embedded section of the patients' primary melanoma (n = 60), relapse (n = 21), and naevus (n = 17) were immunohistochemically double-stained for Ki-67/MART1 and single-stained for CD271, CD166, and CD20. Their whole slide images were aligned as virtual quadruple stains. Image analysis established proliferation indices of each putative stem cell marker and the tumour bulk in addition to the markers' percentage level in tumour areas and the epidermis. In cases vs controls, median dermal proliferation indices (no./mm <superscript>2</superscript> ) were 211 vs 103 (p = 0.04) for CD271, 512 vs 227 (p = 0.3) for CD166, 184 vs 97 (p = 0.3) for CD20, and 95 vs 103 (p = 0.6) for the tumour bulk. Of additional interest, epidermal CD271 <superscript>+</superscript> keratinocytes totalled 8.8% in naevi and 0.98% in melanomas (p = 0.0007). Even though differences between naevi and melanomas also were observed for CD166 in both the epidermis (p = 0.002) and dermis (p = 0.006), they were visually less apparent. CD20 <superscript>+</superscript> MART1 <superscript>+</superscript> cells were absent in half of the melanomas, and all naevi and relapses. In conclusion, high levels of CD271 <superscript>+</superscript> Ki-67 <superscript>+</superscript> MART1 <superscript>+</superscript> cells were linked to melanoma relapse as opposed to common Ki-67 indices in this particular case-control study. With further investigation, such cells could be potential targets of therapy. Especially, loss of epidermal CD271 <superscript>+</superscript> keratinocytes seemed necessary for melanoma development; hence, identification may serve as a diagnostic tool with additional research.<br /> (Copyright © 2018 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.)
- Subjects :
- Adult
Biomarkers, Tumor analysis
Case-Control Studies
Female
Humans
Immunohistochemistry methods
Ki-67 Antigen metabolism
Male
Melanoma diagnosis
Middle Aged
Neoplasm Recurrence, Local diagnosis
Melanoma metabolism
Neoplasm Recurrence, Local metabolism
Neoplastic Stem Cells pathology
Nerve Tissue Proteins metabolism
Receptors, Nerve Growth Factor metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1465-3931
- Volume :
- 50
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Pathology
- Publication Type :
- Academic Journal
- Accession number :
- 29678478
- Full Text :
- https://doi.org/10.1016/j.pathol.2017.12.340